Skip to main content

Table 3 Clinical findings in 41 patients with cardiomyopathy evaluated at > 40 years

From: Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study

 

Infiltrative cardiomyopathy (n = 11)

HCM (n = 30)

p value

Age*, years

68 ± 11

62 ± 11

0.059

Gender: men, n (%)

8 (73 %)

13 (43 %)

0.095

Hs-cTnT*, ng/ml

0.083 ± 0.057

0.025 ± 0.031

<0.001

BNP*, pg/ml

349 ± 301

248 ± 203

0.332

eGFR, ml/min per 1.73 m2

61 ± 17

69 ± 19

0.220

NYHA functional class, n (%)

  

0.124

 I

2 (18 %)

16 (53 %)

 

 II

8 (73 %)

13 (43 %)

 

 III

1 (9 %)

1 (3 %)

 

Hx. of heart failure admission, n (%)

5 (45 %)

6 (20 %)

0.111

Maximum LV wall thickness, mm

17 ± 3

20 ± 4

0.029

Interventricular wall thickness, mm

16 ± 3

16 ± 4

0.562

Posterior wall thickness*, mm

15 ± 3

10 ± 2

<0.001

LV end-diastolic diameter, mm

44 ± 5

45 ± 6

0.877

LV end-systolic diameter*, mm

32 ± 7

28 ± 8

0.161

Ejection fraction, %

54 ± 13

61 ± 13

0.147

Left atrial diameter, mm

44 ± 6

44 ± 9

0.950

E*, cm/s

89 ± 23

69 ± 21

0.019

A, cm/s

67 ± 33

67 ± 19

0.985

E/A*

1.7 ± 1.0

1.1 ± 0.5

0.069

Dct*, msec

208 ± 81

198 ± 70

0.825

Ea septal*, cm/s

3.9 ± 1.1

5.0 ± 2.3

0.226

Ea lateral*, cm/s

4.8 ± 1.3

7.9 ± 3.3

<0.001

E/Ea septal

24 ± 7

16 ± 7

0.002

E/Ea lateral*

20 ± 8

10 ± 4

<0.001

Presence of LVOTO, n (%)

1 (9 %)

5 (17 %)

1.000

Presence of RVH, n (%)

6 (55 %)

14 (47 %)

0.655

  1. Data are shown as mean ± SD or number (percent)
  2. A mark of * is the results of Wilcoxon rank sum test
  3. HCM Hypertrophic cardiomyopathy, Hs-cTnT High-sensitivity cardiac troponin T, BNP Brain natriuretic peptide, eGFR estimated glomerular filtration rate, NYHA, New York Heart Association functional class, LV Left ventricular, LVOTO Left ventricular outflow tract obstruction, RVH Right ventricular hypertrophy